Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
11 déc. 2018 08h00 HE
|
Novan, Inc.
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...
Novan Announces Promising Clinical Results with SB414
20 août 2018 06h30 HE
|
Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
15 mai 2018 08h10 HE
|
Novan, Inc.
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
13 févr. 2018 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term...
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05 déc. 2017 08h35 HE
|
Novan, Inc.
MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
18 oct. 2017 07h05 HE
|
Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
07 juil. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational...
Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
27 avr. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...
Novan Welcomes Key Opinion Leaders to New Advisory Council
04 avr. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion...
Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo
16 nov. 2016 09h05 HE
|
Novan, Inc.
Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model Effect Relates to Multiple Inflammatory Skin Diseases MORRISVILLE, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the...